John Lansing's Trending123
John Lansing's Trending123
Username: Password: Login
Trade Talk E-Letter Products & Services Trading Tools Portfolios Members Home

Stock Sectors

(Click sector to view stock chart)

Medical Instruments Supls

Stock Charts
(Click stock symbol to view stock chart, Support, Resistance, Pivot, Option chain, Volume, P/E, High, Low, Close, Market Cap, Average Volume, Dividend, % Change, $ Change, R1, R2, S1, S2, Previous Close, RSI - MACD - Williams %R - Stochastics - PPO, CMF, ADX, Aroon and more.......)


HemoSense, Inc. engages in the development, manufacture, and sale of handheld blood coagulation monitoring systems for use by patients and healthcare professionals in the management of warfarin medication in the United States and internationally. Warfarin is an oral anticoagulation, or blood thinning, drug given to patients to prevent potentially lethal blood clots. The company's product includes INRatio System, which consists of small and portable meter and disposable test strips and provides measurement of a patient's blood clotting time, known as a PT/INR value. It markets its INRatio System to patient self-testing markets, physician office practices, anticoagulation clinics, hospitals, long-term care facilities, nursing homes, and home healthcare providers primarily through distribution agreements. The company was established in 1997 as CardioSense, Inc. and changed its name to HemoSense, Inc. in 1998. HemoSense is headquartered in San Jose, California.


Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., engages in the development, manufacture, and marketing of medical devices. It operates through three segments: Patient Monitoring Devices, Diagnostic Laboratory Instruments, and Ultrasound Imaging Systems. The Patient Monitoring Devices segment offers approximately 20 different patient monitoring devices for use in hospital intensive care units, operating rooms, and emergency rooms. Its patient monitoring devices are used to track the physiological parameters of patients, such as heart rate, blood pressure, respiration, and temperature. This segment offers various products, including single- and multiple-parameter monitors; mobile and portable multifunction monitors; central stations that collect and display multiple patient data on a single screen; veterinary monitoring devices; anesthesia machines; and an electro-cardiogram monitoring device. The Diagnostic Laboratory Instruments segment provides data and analysis on blood, urine, and other bodily fluid samples for clinical diagnosis and treatment. This segment offers a range of semi-automated and fully-automated diagnostic laboratory instruments for laboratories, clinics, and hospitals. Its products include hematology analyzers and biochemistry analyzers; reagents; and a microplate reader and microplate washer. The Ultrasound Imaging Systems segment sells portable and mobile grayscale ultrasound imaging systems that use computer-managed sound waves to produce real time images of anatomical movement and blood flow; and a range of transducers. Mindray Medical sells its products primarily to distributors, hospitals, clinics, government agencies, original design manufacturers, and original equipment manufacturers. It operates primarily in the People's Republic of China, Europe, North America, and Asia. The company was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.


Tutogen Medical, Inc., together with its subsidiaries, engages in processing, manufacturing, and distributing specialty surgical products made from human (allograft) and animal (xenograft) tissue. It processes human donor tissue utilizing its patented tissue preservation and sterilization process Tutoplast'. The company contracts with independent tissue banks and procurement organizations to provide donated human tissue for processing under the company's proprietary Tutoplast process. Its Tutoplast process utilizes solvent dehydration and chemical inactivation, which is applied to two types of preserved allografts: soft tissue, which consists of fascia lata, fascia temporalis, pericardium, dermis, sclera, ligaments, tendons and cartilage; and bone tissue that includes various configurations of cancellous and cortical bone material. Processed pericardium, fascia lata, and dermis are collagenous tissue used to repair, replace, or line native connective tissue primarily in neurosurgery, ophthalmology, urology procedures, and plastic and reconstructive surgeries; dermis is used in pelvic floor reconstruction; sclera is used in ophthalmology procedures such as, anterior and posterior segment patch grafting applications for glaucoma, retina, and trauma surgery and oculoplastics, as well as contour wrapping of an orbital implant; and ligaments, tendons, and cartilage are used primarily in orthopedic and trauma repairs. Processed cortical and cancellous bone material is used in various applications in spinal and dental surgeries. Tutogen Medical also performs tissue processing services for neuro, orthopedic, reconstructive and general surgical applications. It primarily serves hospitals and surgeons through marketing and distribution partners, direct representatives, and distributors worldwide. The company was founded in 1984 and is headquartered in West Paterson, New Jersey.


Cytyc Corporation engages in the design, development, manufacture, and marketing of clinical products primarily focused on women's health. Its products cover a range of women's health applications, including cervical cancer screening, breast cancer risk assessment, treatment of excessive menstrual bleeding, and treatment of breast cancer. The company operates in two segments, Diagnostic Products and Surgical Products. The Diagnostic Products segment develops and markets the ThinPrep System for use in diagnostic cytology testing applications primarily focused on women's health. The ThinPrep System consists of the ThinPrep 2000 Processor; ThinPrep 3000 Processor; ThinPrep Imaging System; and related reagents, filters, and other supplies, such as the ThinPrep Pap Test and ThinPrep PreservCyt solution. It also provides the platform from which the company has launched its expansion into breast cancer risk assessment with the FirstCyte Breast Test. The Surgical Products segment manufactures and markets the NovaSure System, which allows physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner to eliminate or reduce their bleeding to normal levels. The NovaSure System consists of a single-use disposable device and a controller that delivers radio frequency energy to the lining of the uterus. This segment also offers the MammoSite Radiation Therapy System, a single-use device for the treatment of breast cancer that positions radiation sources directly into the post-lumpectomy site to optimize radiation treatment delivery while minimizing damage to healthy tissue. The company has operations in the United States, the United Kingdom, Germany, France, Switzerland, Spain, Sweden, and Australia. Cytyc was incorporated in 1987 and is headquartered in Marlborough, Massachusetts.


Ventana Medical Systems, Inc. engages in the development, manufacture, and marketing of instrument-reagent systems that automate slide staining in anatomical pathology and drug discovery laboratories worldwide. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in the diagnosis and treatment of cancer and infectious diseases. The company's drug discovery systems are used by pharmaceutical and biotechnology companies to accelerate the discovery of new drug targets and to evaluate the safety of new drug compounds. In addition, Ventana Medical Systems markets consumable products, including reagents and other accessories, required to operate its instruments. Its products are used in immunohistochemistry staining to assist in the diagnosis of cancer and the determination of various treatment options; in situ hybridization staining to assist in the diagnosis of infectious diseases or genetic mutations that are associated with the presence of cancer; and special stains staining to assist in the diagnosis of infectious diseases. The company's customers comprise hospital-based anatomical pathology labs, independent reference labs, the drug discovery labs of pharmaceutical companies, biotechnology companies, government labs, medical research centers, and resellers serving these entities. It offers products primarily in North America, Europe, Japan, and Asia Pacific. Ventana Medical was founded by Thomas M. Grogan in 1985 and is headquartered in Tucson, Arizona.


Kyphon, Inc., a medical device company, engages in the design, manufacture, and marketing of medical devices to treat and restore spinal anatomy using minimally invasive technology. The company's products include KyphX Bone Access Systems, which is used to create a working channel into fractured bone; KyphX Inflatable Bone Tamps, to compact soft inner bone and move hard outer bone; KyphX Xpander Inflation Syringe, to inflate the KyphX Inflatable Bone Tamps; and KyphX Bone Filler Device that deliver bone filler materials into bone cavity. Its products also comprise KyphX Bone Biopsy Device, which takes a sample of bone for evaluation purposes; KyphX Curettes, to scrape or score bone in the spine; and KyphX HV-R polymethylmethacrylate bone cement and KyphOs calcium phosphate, which are bone filler materials used in kyphoplasty procedures. The company's devices are used primarily by spine specialists, including orthopedic surgeons and neurosurgeons, interventional radiologists, and interventional neuroradiologists who repair spinal fractures caused by osteoporosis, trauma, cancer, or benign lesions through kyphoplasty, a minimally invasive surgery. Kyphon sells its products directly in the United States and Europe. The company was founded in 1994 and is headquartered in Sunnyvale, California.


NuVasive, Inc., a medical device company, focuses on the design, development, and marketing of products for the surgical treatment of spine disorders in the United States. The company's principal products include a minimally disruptive surgical platform called maximum access surgery (MAS) and classic fusion products. The MAS platform combines its product offerings, NeuroVision, a proprietary software-driven nerve avoidance system; MaXcess, a split blade-design minimally invasive surgical system; and specialized implantsthat collectively minimize soft tissue disruption during spine surgery. NuVasive's classic fusion portfolio is comprised of a range of products, including spine allografts, which are human bone that has been processed and precision shaped for transplant; and spine implants such as rods, plates, and screws that are necessary for various spine surgery procedures. The company is also developing a proprietary total lateral lumbar disc replacement product and cervical disc replacement product. NuVasive sells its products through its sales agencies and representatives to hospitals. The company was founded in 1995 and is headquartered in San Diego, California.


Rochester Medical Corporation engages in the development, manufacture, and marketing of various latex-free and PVC free urinary continence, and urine drainage care products for the home care, extended care, and acute care markets. The company's extended care products include a line of male external catheters for managing male urinary incontinence and a line of intermittent catheters for managing both male and female urinary retention. The extended care products also include the FemSoft Insert, a soft, liquid-filled, and conformable urethral insert for managing female stress urinary incontinence in adult females; and Personal Catheters, a line of disposable intermittent catheters manufactured from silicone for male, female, and pediatric use and in multiple diameters. Its acute care products include a line of standard Foley catheters; and Release-NF Catheter, an antibacterial Foley catheter that reduces the incidence of hospital acquired urinary tract infection. The company also offers standard silicone Foley catheters in a two-lumen version for urinary drainage management and in a three-lumen version that also supports irrigation of the urinary tract. In addition, it manufactures and sells male external catheters made from proprietary nonlatex, nonsilicone material to certain private label customers. The company markets its products through a direct sales force in the United States and independent distributors in international markets. Rochester Medical Corporation was founded in 1988 and is based in Stewartville, Minnesota.


China Medical Technologies, Inc. develops, manufactures, and markets medical devices for the treatment of solid cancers and benign tumors in the People's Republic of China. It offers In-vitro diagnostics systems, which include enhanced chemiluminescence immunoassay (ECLIA) system and fluorescent in situ hybridization (FISH) imaging analysis system and probes. The company's ECLIA system consists of ECLIA analyzer for detecting minute levels of light triggered by combining reagents with body fluid samples to produce diagnostic results; reagent kits, which are formulated to create various reactions with blood or other body fluid samples; and a data analysis system to analyze and organize the information produced form diagnostic results. It offers 62 types of reagent kits for use with the ECLIA analyzer for detecting and monitoring various types of diseases and disorders, including thyroid disorders, diabetes, hepatitis, and disorders related to reproduction and growth, SARS, Down syndrome, liver fibrosis, and various types of tumors. China Medical Technologies also offers FISH imaging analysis system and probes, which uses FISH technology for prenatal and postnatal diagnosis, and early detection and prognosis of various cancers. In addition, the company provides HIFU therapy system to treat liver, breast, and kidney tumors; solid tumors in the pelvic cavity or on bone; and tumors in the four limbs or superficial tissues. It sells its products through direct sales force and distributors. China Medical Technologies was founded in 1999 and is based in Beijing, the People's Republic of China.


The Aristotle Corporation and its subsidiaries engage in the manufacture and distribution of educational, health, medical technology, and agricultural products. It operates in two segments, Educational and Commercial. The Educational segment primarily sells supplemental educational supplies and equipment to school districts, individual schools, teachers, and curriculum specialists, who purchase products for school and classroom use. In addition, the company sells medical technology training products, including manikins and simulation kits used for training in cardiopulmonary resuscitation and the emergency rescue, and patient care fields. The company's primary customers for its health care training products are fire and emergency medical departments, and nursing and medical schools. The Commercial segment markets agricultural supplies, and small hand tools and equipment to farmers and ranchers to assist in animal livestock and crop production. In addition, the company provides sterile sampling bags and containers. Its product line is primarily sold to the food industry, including water treatment facilities. The company distributes its products through catalogs, Web sites, and distributors to customers in the United States and internationally. The Aristotle Corporation was founded in 1986 and is headquartered in Stamford, Connecticut.


Atrion Corporation engages in the design, development, manufacture, marketing, sale, and distribution of various products and components, primarily for the medical and health care industry worldwide. It offers ophthalmology products, which include LacriCATH product line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. The company's cardiovascular products comprise MPS Myocardial Protection System that delivers essential fluids and medications to the heart during open-heart surgery; cardiac surgery vacuum relief valves; Retract-O-Tape silicone vessel loops; and Clean-Cut rotating aortic punch, used in heart bypass surgery. It also offers intravenous fluid delivery line for therapy procedures employed in anesthesia administration, intravenous feeding, intensive care, and cancer therapy. Atrion manufactures valves, tubing flanges, right angle connectors, and closures for life vests, life rafts, inflatable boats, inflatable toys, survival equipment, and other inflatable structures, as well as various one-way and two-way 'Breather' valves for use on electronics cases, munitions cases, pressure vessels, lift bags, space suits, mattresses, escape slides, and other application requiring pressure relief for use in aviation and marine safety products. In addition, the company provides contract manufacturing services for other original equipment manufacturers of medical devices, as well as warehousing and inventory management services. It offers pressure monitoring kits for use in labor and delivery procedures and various critical care applications. Further, the company owns and maintains a 22-mile high-pressure steel pipeline in north Alabama that is leased to an industrial gas producer that transports gaseous oxygen. Atrion markets its components to other equipment manufacturers; and sells finished devices to physicians, hospitals, clinics, and other treatment centers. The company is headquartered in Dallas, Texas.


Osteotech, Inc. engages in processing human bone and connective tissue for transplantation, as well as development, manufacture, and marketing of biologic, biomaterial, and device systems for musculoskeletal surgery. It focuses on spinal, trauma, and total joint revision procedures. The company provides services, and develops, markets, and sells products to the orthopaedic, neurological, oral/maxillofacial, and general surgery markets in the United States and Europe. It offers demineralized bone grafts, structural allografts, and other allografts. The company's demineralized bone matrix and base tissue processing yields various freeze-dried, frozen, and demineralized allograft bone tissue forms that are used by orthopaedic, neurological, plastic, periodontal, and oral/maxillofacial surgeons. Its products are used for spinal fusion procedures; repair and replacement of bone loss caused by trauma or certain disease states; augmentation of prosthetic implant procedures; and replacement of damaged ligaments and tendons. The company processes and develops human bone and bone connective tissue, or allograft bone tissue forms. It also processes, markets, and distributes bovine bone tissue products, which are utilized as bone graft substitutes by surgeons in Europe, Asia, and the Middle East. The company was formed in 1986 and is based in Eatontown, New Jersey.


Cardica, Inc. designs and manufactures proprietary automated anastomotic systems used by surgeons to perform coronary artery bypass surgery. The company's products include C-Port Distal Anastomosis System, which is designed to perform an end-to-side distal anastomosis by attaching the end of a bypass vein graft to a coronary artery downstream of an occlusion or narrowing; C-Port xA Distal Anastomosis System, an enhanced C-Port system, which includes a change from a spring-driven to a gas release-driven stapling mechanism, as well as incorporates non-traumatic vessel clamps and safety mechanisms; and C-Port Flex A Anastomosis System, which includes modifications to the C-Port xA system that are designed to enable automated anastomoses to be performed as part of minimally invasive and robot-facilitated CABG procedures. Its products also comprise PAS-Port Proximal Anastomosis System, an automated device used to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. In addition, the company develops the Cook Vascular Closure Device to be used in interventional vascular procedures. Cardica has an agreement with Cook Incorporated for the development of the Cook Vascular Closure Device, as well as to develop and commercialize a specialized device to close the PFO. It primarily sells the C-Port systems in the United States and Europe, and the PAS-Port systems in Europe and in Japan through distributors. The company was founded in 1997 as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in 2001. Cardica is headquartered in Redwood City, California.


EP MedSystems, Inc. engages in the development, manufacture, and marketing of a line of products for the cardiac electrophysiology market. The company's products are used to diagnose, monitor, visualize, and treat irregular heartbeats known as arrhythmias. Its products include EP-WorkMate, a computerized electrophysiology workstation that monitors, displays, and stores cardiac electrical activity and arrhythmia data; EP-3 stimulator; the RealTime Position Management navigation technology; EP-4 computerized cardiac stimulator; diagnostic electrophysiology catheters; and ALERT System, which uses an electrode catheter to deliver bi-phasic electrical impulses directly to the inside of the heart to convert atrial fibrillation to a normal heart rhythm in the treatment of atrial fibrillation. The company also offers ViewMate intracardiac ultrasound catheter system that provides visualization to the inside chambers of the heart, as well as related disposable supplies. EP MedSystems sells its products primarily to medical institutions and physicians in the United States and France. It has strategic alliances with Boston Scientific Corporation and Philips Medical. The company was founded by David A. Jenkins in 1993 and is headquartered in West Berlin, New Jersey.


Strategic Diagnostics, Inc. engages in the development, manufacture, and marketing of antibody products and analytical test kits for a range of food, water, agricultural, industrial, environmental, and scientific applications primarily in the United States. It primarily focuses on immunology, proteomics, bio-luminescence, and other bio-reactive technologies. The company offers monoclonal and polyclonal antibody products and services in the areas of hybridoma development, cell culture techniques, large-scale ascites and antisera production, large-scale antibody purification, chemical modification of immunogens and antibodies, and characterization of antibodies and a range of related services. It also manufactures a line of human-serum-based calibrators for serum protein markers. The company's antibody products and services sells its products to pharmaceutical, biotechnology and diagnostic companies, and biomedical research centers under Strategic BioSolutions brand name. Its food safety product line includes enrichment media and rapid tests to detect food pathogens. The company's water quality products include analytical tests for drinking water, industrial process water and wastewater analysis, and analytical tests for soil and other waste matrices for use at environmental remediation projects, hazardous waste operations, and other applications. Strategic Diagnostics markets and sells its products in the food safety, water quality, and life science antibody markets through direct sales force, Internet, and distributors in Canada, Mexico, Latin America, Europe, and Asia. The company was founded in 1987 and is headquartered in Newark, Delaware.


Stryker Corporation engages in the development, manufacture, and marketing of orthopedic products and medical specialties worldwide. It operates in two segments, Orthopedic Implants and MedSurg Equipment. The Orthopedic Implants segment sells orthopedic reconstructive, trauma, spine and micro implant systems, bone cement, and the bone growth factor OP-1 products. The MedSurg Equipment segment offers powered surgical instruments, surgical navigation systems, endoscope products, medical video imaging equipment, and hospital beds and stretchers. The company also provides outpatient physical therapy services to its customers that includes physical, occupational, and speech therapy services to patients recovering from orthopedic or neurological illness and injury. Its products are sold in approximately 100 countries through local dealers and direct sales efforts. The company was founded in 1941 and is headquartered in Kalamazoo, Michigan.


PerkinElmer, Inc. provides scientific instruments, consumables, and services to the pharmaceutical, biomedical, environmental testing, chemical, and general industrial markets worldwide. It designs, manufactures, markets, and services products and systems in three segments: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. The Life and Analytical Sciences segment provides drug discovery, genetic screening, and environmental and chemical analysis tools, including instruments, reagents, consumables, and services for daily applications in scientific research and clinical applications. Its products are offered under various brand names, including Wallac, Packard, NEN, AAnalyst, Clarus, OneSource, LABWORKS, Pyris, Spectrum, Optima, DELFIA, ImageTrak, UltraView, prOTOF, Victor, LANCE, ELAN, and ViewLux. The Optoelectronics segment provides digital imaging, sensor, and specialty lighting components used in the biomedical, consumer products, and other specialty end markets under the brand names Cermax, Heimann, ColdBlue, MultiBlue, Power Systems, Amorphous Silicon, and Reticon. The Fluid Sciences segment provides fluid control and containment systems for environments, such as turbine engines and semiconductor fabrication facilities under the brand names Belfab, Callisto, Centurion, U-Plex Seals, E-Seals, Rigid E-Seal Joints, and PressureScience. The company was founded in 1947 and is headquartered in Wellesley, Massachusetts. PerkinElmer, Inc. acquired Elcos AG in February 2005, which designs and manufactures custom light emitting diode and solutions for biomedical and industrial applications.


OraSure Technologies, Inc. engages in the development, manufacture, and marketing of oral specimen collection devices. Its products include Q.E.D. Saliva Alcohol Test and Intercept, a laboratory-based oral fluid drug test; OraSure HIV-1 oral fluid specimen device, a collection device that collects oral fluid to test for antibodies to the HIV-1 virus; OraQuick Rapid HIV-1 antibody test, a point-of-care test to aid in the diagnosis of infection to HIV-1 using a fingerstick and venipuncture whole blood specimen; Toxicology kits for use in testing blood, urine, hair, oral fluid, sweat, and other forensic samples. The company also offers enzyme immunoassay test kits and oral fluid collection devices, which are used to perform risk assessment testing of life insurance applicants and screen for drugs of abuse, nicotine use, and therapeutic drugs, to insurance laboratory clients; OraSure, a set of MICRO-PLATE products to the blood fractionation market for testing of plasma and related products; Cryosurgery for treating various superficial benign skin lesions, including warts, actinic keratoses, seborrheic keratoses, skin tags, age spots, condyloma acuminate, and molluscum; and Histofreezer portable cryosurgical system for cryosurgery. The company sells its products in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is headquartered in Bethlehem, Pennsylvania.


DENTSPLY International, Inc. and its subsidiaries engage in the design, development, manufacture, and marketing of a range of professional dental products worldwide. The company's principal dental products include dental consumables, including dental anesthetics, prophylaxis paste, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride; dental laboratory products which include dental prosthetics, such as artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and dental specialty products, including endodontic instruments and materials, implants, and orthodontic appliances and accessories. DENTSPLY International distributes its products through domestic and foreign distributors, dealers, and importers, as well as directly to the dental laboratory or dental professionals. DENTSPLY International is headquartered in York, Pennsylvania.


VIVUS, Inc., a pharmaceutical company, engages in the research, development, and commercialization of products to restore sexual function in women and men. Its product pipeline includes four clinical stage product candidates, including ALISTA for the treatment of female sexual arousal disorder; Testosterone-MDTS to treat hypoactive sexual desire disorder; Evamist to alleviate symptoms associated with menopause; and Avanafil, an inhibitor product candidate for the treatment of erectile dysfunction. ALISTA and Evamist are in Phase 3 trials; and Testosterone-MDTS and Avanafil are in Phase 2 trials. The company also markets MUSE, a transurethral applicator used for treating erectile dysfunction, in the United States and internationally through distribution partners. It has a development, license, and supply agreement with Tanabe Seiyaku Co., Ltd., for the development and commercialization of avanafil; and licensing agreements with Acrux Limited to develop and commercialize testosterone-MDTS and Evamist in the United States for various female health applications. VIVUS was founded by Virgil A. Place in 1991 and is headquartered in Mountain View, California.


Thoratec Corporation manufactures circulatory support products for use by patients with congestive heart failure. The company operates in two segments, Cardiovascular and International Technidyne Corporation (ITC). The Cardiovascular segment develops, manufactures, and markets medical devices used for circulatory support products, which include ventricular assist device for the short-term and long-term treatment of congestive heart failure, as well as vascular graft products for use as a shunt between an artery and a vein. It offers a product portfolio of implantable and external circulatory support product devices, including the Thoratec Implantable Ventricular Assist Device, a biventricular implantable blood pump; the HeartMate Left Ventricular Assist System (LVAS), an implantable device for mid to long-term cardiac support for those patients ineligible for heart transplantation; and the HeartMate II, an implantable LVAS consisting of a miniature rotary blood pump that is designed to provide long-term support. These products are sold into the hospital point-of-care (POC) market, and the alternate site POC market comprising physician's offices, long-term care facilities, clinics, visiting nurse associations, and home healthcare companies. ITC segment designs, develops, manufactures, and markets point-of-care diagnostic test systems that monitor a patient while being administered certain anticoagulants, blood gas/electrolyte, and chemistry status or anemia; and incision products to obtain a patient's blood sample for diagnostic testing and screening for platelet function. The company markets its products through direct sales force and distributors in the United States, Canada, France, Germany, Spain, the United Kingdom, Austria, Switzerland, the Netherlands, Portugal, and South Africa. Thoratec Corporation was founded in 1976 and is headquartered in Pleasanton, California.


AtriCure, Inc. engages in the development, manufacture, and sale of surgical devices designed to create precise lesions, or scars, in cardiac and soft tissues. It offers the AtriCure Isolator bipolar ablation system, which consists of an ablation sensing unit, a compact power generator that uses its proprietary software and delivers bipolar radio-frequency energy; multiple configurations of its Isolator bipolar ablation clamps; and its multifunctional bipolar Pen. The company also provides Isolator bipolar ablation clamps designed for ablation during open procedures; Isolator Synergy ablation clamps, which are designed to provide full thickness lesions in thicker and more diseased tissues; and endoscopic Isolator bipolar ablation clamps designed for use in minimally invasive procedures. In addition, it offers multifunctional bipolar Pen for the surgical ablation of cardiac tissue; and for temporary pacing, sensing, stimulating, and recording during the evaluation of cardiac arrhythmias. Further, the company sells Lumitip dissector for the dissection of soft tissues during general, thoracic, and certain other surgical procedures; and distributes cryoablation devices that use extreme cold to ablate tissue. AtriCure sells its medical devices through its direct sales force to hospitals and medical clinics primarily in the United States, as well as through distributors in Asia, Europe, Canada, the Middle East, Central America, and South America. The company was founded in 2000 and is headquartered in West Chester, Ohio.


Alcon, Inc. engages in the development, manufacture, and marketing of pharmaceuticals, surgical equipment and devices, and consumer eye care products to treat diseases and disorders of the eye. Its pharmaceutical products include a line of products to treat glaucoma; anti-infectives, anti-inflammatories, and combination therapies to treat bacterial, viral, and fungal infections of the eye, as well as to control ocular inflammation; products for the treatment of ocular allergies; and generic ophthalmic products and otic pharmaceuticals. The company offers various surgical products, including surgical procedure packs for cataract, vitreoretinal, and refractive surgeries. The single-use products for cataract procedures include cassettes used in the LEGACY and Infiniti vision systems, a line of viscoelastics to protect delicate tissues of the eye during the procedure, surgical knives, and surgical irrigating solutions. The products for vitreoretinal surgery include Accurus surgical system, which integrates all automated and nonlaser surgical functions, and performs phaco procedures for cataract removal. The laser refractive surgical equipment include LADARWave aberrometer, a wave front device that measures refractive errors of the optical system; LADARVision 4000 excimer laser system to combine an active laser radar eye tracker; and a true small-spot laser beam to deliver to surgeons for the treatment of refractive patients. The company's consumer eye care products consist of a line of contact lens care products, artificial tears, and ocular vitamins. Alcon sells its products through sales representatives and distributors in approximately 180 countries. The company was founded in 1945. Alcon was formerly known as Societe Fromagere Nestle S.A. and changed its name to Alcon Universal S.A. in 1978. Further, it changed its name to Alcon, Inc. in 2001. The company is headquartered in Hunenberg, Switzerland. Alcon, Inc. is a subsidiary of Nestle S.A.


I-Flow Corporation engages in the design, development, manufacture, and marketing of ambulatory infusion systems for pain management and infusion therapy. It manufactures a line of infusion pumps, catheters, and pain kits that administer medication directly to the wound site, as well as administer local anesthetics, chemotherapies, antibiotics, diagnostic agents, nutritional supplements, and other medications. The company sells and distributes its products in the United States, Canada, Europe, Asia, Mexico, Brazil, Australia, New Zealand, and the Middle East. In addition, it engages in the rental of infusion pumps on a month-to-month basis for the treatment of cancer. I-Flow Corp. has a partnership with the University of Minnesota to conduct an animal study to evaluate the promise of antimicrobial benefits of ON-Q. The company was established in 1985 and is headquartered in Lake Forest, California.


SonoSite, Inc. engages in the development, manufacture, and sale of hand-carried ultrasound imaging systems for use in clinical applications and settings. Its products are used for imaging in a variety of medical specialties, such as radiology, obstetrics and gynecology, emergency medicine, surgery, cardiology, internal medicine, and vascular medicine. The company's products include SonoSite 180PLUS system for general ultrasound imaging, SonoHeart ELITE for cardiovascular applications, and the SonoSite TITAN system for general imaging and cardiology applications. Its products also include the iLook 25, an imaging tool designed to provide visual guidance for physicians and nurses while performing vascular access procedures, as well as iLook 15, also an imaging tool designed to provide visual imaging of the chest and abdomen for physicians and nurses while performing other procedures and examinations. In addition, the company offers a selection of accessories, including mobile docking stations, multiple transducer connections, image transfer and management software, printers, VCRs, auxiliary monitors, storage devices, carrying cases, and disposable supplies for its products. SonoSite, Inc. sells its products through direct sales representatives and their managers, independent third-party distributors, and strategic alliances in the United States, the United Kingdom, Germany, France, Spain, Japan, Australia, and Canada. SonoSite was incorporated in 1986 and is headquartered in Bothell, Washington.


Integra LifeSciences Holdings Corporation engages in the development, manufacture, and marketing of medical devices for use in neuro-trauma, neurosurgery, reconstructive surgery, and general surgery. Its product groups include monitoring products, implants, instruments, and private label products. The company's monitoring products include intracranial pressure (ICP) monitoring systems, cerebral blood flow and ICP systems, oxygen monitoring systems, cranial access and cerebrospinal fluid drainage systems, epilepsy monitoring electrodes, and electroencephalogram, evoked potential, and electromyography electrodes, as well as disposables and other supplies. Its implants include absorbable collagen products, skin replacement and engineered wound dressings, hydrocephalus management products, peripheral nerves repair and protection products, hydrocephalus management, small bone and joint fixation devices and instruments, and hemodynamic shunts. The company's instruments include ultrasonic aspirator, cranial stabilization and positioning systems, halo retractor system, electro-surgery generators, neurosurgical and spinal instruments, reconstructive and plastic surgery instruments, harvesting and conditioning skin grafts devices, and spinal specialties. Integra LifeSciences sells its products primarily through catalogs and telemarketing to neurologists, hospitals, sleep clinics, and other physicians. The company also distributes various disposables and supplies, including surface electrodes, needle electrodes, recording transducers and stimulators, and respiratory sensors. Integra LifeSciences Holdings was founded in 1989 and is based in Plainsboro, New Jersey.


Cardiac Science Corporation engages in the development, manufacture, and marketing of diagnostic and therapeutic cardiology products and services in the United States and internationally. Its products include automated external defibrillators; electrocardiographs that allow physicians to record and analyze patient ECG waveforms; cardiac stress testing systems, which enable cardiologists and other healthcare providers to monitor and analyze the performance of the heart under stress; Holter monitoring systems, which record the patient's heart rate, heart rhythm, and electrocardiograph waveform data during various activities; and cardiac rehabilitation telemetry systems that enable cardiologists and other healthcare providers to track and assess improvements in cardiovascular function. The company's products also comprise cardiology data management systems that automate the processing, storage, retrieval, and editing of electrocardiographic data. In addition, it supplies lead wires and electrodes used in the retrieval and processing of patient ECGs; thermal chart paper to generate reports; and a line of other complementary cardiology-related products, such as blood pressure monitors and spirometers. The company markets its products under the Burdick, Powerheart, and Quinton brand names. Cardiac Science Corporation was founded in 1953 and is headquartered in Bothell, Washington.


DexCom, Inc., a development stage medical device company, focuses on the design and development of continuous glucose monitoring systems for people with diabetes. The company primarily develops two continuous glucose monitoring systems, including a short-term system with a sensor that can be inserted by a patient; and a long-term system with a sensor that can be implanted by a physician. DexCom was incorporated in 1999 and is headquartered in San Diego, California.


Baxter International, Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease, and trauma worldwide. The company operates in three segments: Medication Delivery, BioScience, and Renal. The Medication Delivery segment provides various intravenous solutions and specialty products that are used in combination for fluid replenishment, general anesthesia, nutrition therapy, pain management, antibiotic therapy, and chemotherapy. The BioScience segment develops biopharmaceuticals, biosurgery products, vaccines and blood collection, and processing and storage products and technologies for transfusion therapies. The Renal segment develops products and provides services to treat end-stage kidney disease. The company's products are used by hospitals, clinical and medical research laboratories, blood and plasma collection centers, kidney dialysis centers, rehabilitation centers, nursing homes, doctors' offices, and by patients at home under physician supervision. It distributes its products through independent distributors, drug wholesalers acting as sales agents, and specialty pharmacy or homecare companies. Baxter International has collaborative agreements with Nektar Therapeutics to develop PEGylated therapeutic forms of blood clotting proteins for patients with hemophilia, in order to reduce the frequency of injections required to treat blood clotting disorders, such as hemophilia; and with Lipoxen Technologies, Ltd. to develop longer acting therapeutic forms of blood clotting proteins. The company was founded in 1931 and is based in Deerfield, Illinois.


Cantel Medical Corp. provides infection prevention and control products for the healthcare market. Its Dialysis segment includes disinfection/sterilization reprocessing equipment, sterilants, supplies, and concentrates for hemodialysis treatment of patients with acute kidney failure or chronic kidney failure, as well as offers technical maintenance services. The company's Dental segment comprises single-use infection control products used in the dental market, such as face masks, patient towels and bibs, self-sealing sterilization pouches, tray covers, sterilization packaging accessories, surface barriers, disinfectants and deodorizers, germicidal wipes, hand care products, gloves, sponges, cotton products, cups, needles and syringes, scalpels and blades, and saliva evacuators and ejectors. Its Endoscopy and Surgical segment includes diagnostic and therapeutic medical equipment, such as endoscopes, surgical equipment, and related accessories. The company's Endoscope Reprocessing segment consists of endoscope disinfection equipment, and related accessories and supplies. Its Water Purification and Filtration segment includes water purification equipment design and manufacturing, project management, installation, maintenance, deionization, and mixing systems, as well as hollow fiber filter devices and ancillary products for fluid and separation applications for the medical, pharmaceutical, biotechnology, research, beverage, and semiconductor industries. In addition, the company offers microscopes, image analysis hardware and related accessories; and industrial technology equipment, such as borescopes, fiberscopes, and video image scopes. It also offers specialized packaging for the safe transport of infectious and biological specimens, and compliance training services. Cantel Medical has operations in Singapore, Taiwan, China, the Netherlands, the United Kingdom, and the United States. The company was founded in 1963 and is based in Little Falls, New Jersey.


Becton, Dickinson and Company engages in the manufacture and sale of medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company has three segments: Medical, Diagnostics, and Biosciences. The Medical segment offers needles, syringes, and intravenous catheters, including safety-engineered devices for medication delivery; insulin injection devices and blood glucose monitors for the treatment of diabetes; prefillable drug delivery devices to pharmaceutical companies and end-users as drug/device combinations; surgical blades and regional anesthesia needles; critical care monitoring devices; ophthalmic surgery devices; sharps disposal containers; and home healthcare products. The Diagnostics segment provides integrated systems for evacuated blood collection, a line of safety-engineered specimen collection products and systems, plated media, automated blood culturing, molecular testing systems for sexually transmitted diseases, microorganism identification and drug susceptibility systems, and manual testing products. The Biosciences segment includes fluorescence activated cell sorters and analyzers, cell imaging systems, monoclonal antibodies and kits, reagent systems for life sciences research, tools to aid in drug discovery and growth of tissue and cells, and diagnostic assays. It serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public, primarily through independent sales representatives and independent distribution channels. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.


Uroplasty, Inc., a medical device company, engages in the development, manufacture, and marketing of products for the treatment of voiding dysfunctions, including urinary and fecal incontinence, and overactive bladder symptoms. It primarily offers Macroplastique implants, a minimally invasive, implantable soft tissue bulking agent for the treatment of urinary incontinence; PTQ implants for the treatment of fecal incontinence; VOX implants for the treatment of vocal cord rehabilitation; and Bioplastique implants for dermal augmentation. The company also offers Urgent PC neuromodulation system, a device designed for office-based treatment of overactive bladder symptoms of urinary urge incontinence, urinary urgency, and urinary frequency; and I-Stop, a biocompatible, polypropylene, tension-free sling for the treatment of female urinary incontinence. Uroplasty markets its products through direct field sales and independent sales representatives in the United States; and a direct sales organization in the United Kingdom, as well as through distributors in other markets. The company was incorporated in 1992 and is headquartered in Minnetonka, Minnesota.


C. R. Bard, Inc. (Bard) engages in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices. It has four product groups: Vascular, Urology, Oncology, and Surgical Specialties. In the Vascular products group, the company offers products for the peripheral vascular market. These products include percutaneous transluminal angioplasty catheters, guidewires, introducers and accessories, peripheral stents, vena cava filters, and biopsy devices; electrophysiology products, including diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. In the Urology products group, Bard offers foley catheters; surgical sling and injectable tissue bulking products that are used to treat stress urinary incontinence; natural and synthetic materials for the treatment of pelvic floor or vaginal prolapse; brachytherapy services, devices, and radioactive seeds that are used to treat prostate cancer; urine monitoring and collection systems; ureteral stents; and specialty devices for ureteroscopic procedures and stone removal. The company's Oncology products include devices used in the treatment and management of various cancers, and other diseases and disorders. These include specialty access catheters, ports, and enteral feeding devices. Bard's Surgical Specialty products include meshes for hernia and other soft tissue repairs; irrigation devices for orthopedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. It sells its products to hospitals, individual health care professionals, extended care facilities, and alternate site facilities worldwide. Bard distributes its products directly and through distributors. The company was founded in 1907 by Charles Russell Bard and is headquartered in Murray Hill, New Jersey.


LeMaitre Vascular, Inc. engages in the development, manufacture, and marketing of disposable and implantable vascular devices for the treatment of peripheral vascular disease. The company's products include EndoFit Thoracic Stent Graft used for the repair of thoracic aortic aneurysm and dissection; UniFit Abdominal Stent Graft for abdominal aortic aneurysm; VascuTape Radiopaque Tape for the improvement of endovascular procedures; AnastoClip Vessel Closure System for the attachment of blood vessels, primarily for dialysis access; Expandable LeMaitre Valvulotome for destructing vein valves to create vein bypass graft; Pruitt-Inahara and Pruitt F3 Carotid Shunts for the facilitation of blood flow to brain during carotid plaque removal; and InvisiGrip Vein Stripper, a single-incision removal of varicose veins. Its product portfolio also comprise LeMaitre Balloon Catheters for the removal of blood clots, occlusion, and facilitation of blood flow; Reddick Cholangiogram Catheter for the introduction of dye into the cystic duct; and OptiLock Implantable Port, a central venous infusion of drugs and nutrients. The company sells its products to vascular surgeons and interventionalists through direct sales force and a network of distributors in the United States, Canada, and internationally. LeMaitre Vascular was founded in 1983. It was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in 2001. The company is headquartered in Burlington, Massachusetts.


BioMimetic Therapeutics, Inc. engages in the development and commercialization of bio-active drug-device combination products for healing musculoskeletal injuries and diseases that include periodontal, orthopedic, spine, and sports injury applications. It primarily engages in the development of the treatment for bone loss associated with advanced periodontal disease, and repair and regeneration of orthopedic tissues, including bone, cartilage, and ligaments or tendons. The company's GEM 21S Growth-factor Enhanced Matrix (GEM) is a synthetic regeneration system that combines a recombinant human platelet-derived growth factor with a synthetic bone matrix called beta-tricalcium phosphate in order to treat periodontal bone defects and gum tissue recession associated with periodontal diseases. It also develops GEM product candidates in the field of orthopedics, including bone, tendon, ligament, and cartilage applications. The company also develops GEM OS1 for the treatment of open fractures; GEM OS2 for the treatment of closed fractures; and other GEM OS product candidates for the areas of the skeletons, such as the vertebral bodies of the spine in osteoporotic individuals that are susceptible to fracture, and where stimulation of new bone formation could have a prophylactic therapeutic benefits. In addition, the company's pre-clinical development products include GEM C and GEM LT, which are used for various sports injuries, including those requiring cartilage, ligament, and tendon repair. Further, it offers GEM ONJ for treating osteonecrosis of the jaws. BioMimetic Therapeutics has a partnership with Luitpold Pharmaceuticals, Inc. for the marketing and distribution of GEM 21S worldwide. The company was founded in 1999. It was formerly known as BioMimetic Pharmaceuticals, Inc. and company changed its name to BioMimetic Therapeutics, Inc. in 2005. BioMimetic Therapeutics is headquartered in Franklin, Tennessee.


AMDL, Inc., a theranostics company, engages in both the detection and treatment of cancer. It develops, manufactures, markets and sells various immunodiagnostic kits. Its products include DR-70, a test kit that is used in the detection of approximately 13 different types of cancer, including lung, stomach, breast, rectal, colon, and liver; and Pylori-Probe, which is cleared for sale in the United States. The company also offers private label test kits to underserved international markets through distributor relationships and to domestic markets through strategic partnerships and relationships with diagnostic companies. AMDL was incorporated in 1988 and is based in Tustin, California.


Daxor Corporation operates as a medical device manufacturing and biotechnology company in the United States. It is developing BVA-100, which measures human blood volume. This instrument is used in conjunction with a single use radiopharmaceutical diagnostic injection kit known as Volumex. BVA-100 has an accuracy of approximately 98% while also providing the predicted normal blood volume for that specific individual based on the height, weight, and sex of the patient. Daxor's patented Volumex utilizes Albumin I-131, a classic tracer used for blood volume measurement. The company, through its wholly owned subsidiary, Scientific Medical Systems, operates a frozen blood bank in New York that allows people to store their own blood utilizing cryobiology technology for approximately 10 years. In addition, Idant, a division of the Scientific Medical subsidiary, provides sperm banking services. The company also provides special screening for rare hereditary recessive genetic traits. Daxor was founded in 1970 and is based in New York City.


Alphatec Holdings, Inc. engages in the design, development, manufacture, and marketing of products for the surgical treatment of spine disorders. It offers spine screws, spinal spacers, and plates. The company's products include fusion systems that are used to facilitate the growth of a boney connection; lumbar fixation system, a spinal system, which offers fixed angle pedicle screws, polyaxial pedicle screws, and advanced instrument design; spinal fixation system designed to allow the rod to be placed closer to the center of the patient's body; ROC lumbar plating system, a posterior lumbar plating system that provides an alternative to traditional screw and rod constructs; and deformity system. Its product portfolio also comprise tamarack anterior thoracolumbar plating system; trauma/tumor fixation system for use in anterior thoracolumbar fixation for the treatment of tumor, trauma, and anterior deformity; anterior cervical plate system, which consists of fixed hole plates and a locking mechanism that allow screws to be set at variable angles; and reveal anterior cervical plate system that allows the surgeon to visualize the graft site during surgery. In addition, Alphatec offers posterior cervical/thoracic fusion system comprising rods, polyaxial screws, and offset connectors; PEEK and titanium spacers; allograft spacers; Alphagraft product that is used for bone grafting; and Alphagrans product, which are bioabsorbable synthetic granules. Further, the company develops Connect II allograft spacer, minimally invasive system, occipital plate for placement at the base of the skull in posterior fusion procedures, ALIF plate system designed for anterior lumbar interbody fusion, dynamic cervical plate system, and dynamo rod that allows for controlled compression and distraction of vertebrae adjacent. Alphatec sells its products through independent distributors in the United States and Japan. The company was founded in 1990 and is headquartered in Carlsbad, California.


Conceptus, Inc. engages in the development, manufacture, and marketing of medical products for women's health in the United States. The company offers Essure, a permanent birth control device for women that provides a nonincisional alternative to tubal ligation. It markets its product primarily in Australia, Canada, Europe, Indonesia, Singapore, and the United States. Conceptus was founded in 1992 and is headquartered in San Carlos, California.


Vital Signs, Inc. engages in the design, manufacture, and marketing of medical products for the anesthesia, respiratory, critical care, neonatal, sleep therapy, and emergency markets. It operates in four segments: Anesthesia, Respiratory/Critical Care, Sleep Disorder, and Pharmaceutical Technology Services. Anesthesia segment offers single-patient use anesthesia breathing circuits; face masks; general anesthesia systems. These products comprise air-filled cushion face masks, breathing circuits, and temperature monitoring probes; single limb breathing circuits; single use airway devices; and fiberoptic laryngoscope systems. This segment also manufactures and sells introducers, sheaths, dilators, hemostasis valves, and catheters. Respiratory/Critical Care segment provides disposable arterial blood gas syringes and collection systems, manual resuscitators, hyperinflation systems, blood pressure cuffs, face masks, respiratory product lines that deliver hydration to a patient, cardiopulmonary resuscitation training manikins, and pediatric emergency system. Sleep Disorder segment offers sleep disorder/personal ventilation products that include continuous positive airway pressure flow generators, humidification systems, sleep disorder home screening devices, life support ventilator, and other ventilators. This segment also provides diagnostic and therapeutic services for sleep disorders. Pharmaceutical Technology Services segment offers consulting services to medical device, diagnostic, and biotechnology companies, which help them to develop and validate systems and processes for their manufacturing, infrastructure, research and development, and laboratory and quality assurance departments. The company serves various hospitals, surgery centers, and health care providers primarily in the United States, Europe, and Asia. Vital Signs was founded by Terry D. Wall in 1972 and is headquartered in Totowa, New Jersey.


Luminex Corporation engages in the design, development, manufacture, and marketing of proprietary biological testing technologies with applications throughout the life sciences industry. The company's xMAP technology enables its Luminex 100 System to simultaneously perform up to 100 bioassays on a single drop of fluid by reading biological tests that are taking place on the surface of microscopic polystyrene beads called microspheres. The xMAP technology is used in various segments of the life sciences industry, including the fields of drug discovery and development, clinical diagnostics, genetic analysis, protein analysis, and biomedical research. The company's customers include clinical diagnostic, pharmaceutical, biotechnological, and chemical companies. Luminex Corp. has an agreement with Biohit Oyj for the development and commercialisation of a diagnostic test system segment. The company was incorporated in 1995 and is based in Austin, Texas.


Haemonetics Corporation engages in the design, manufacture, and marketing of automated systems and single-use disposables for the collection, processing, and surgical salvage of donor and patient blood. The company's systems enable users to collect and process the blood component they target, such as plasma, platelets, or red blood cells. Its products include PCS brand systems, which automate the collection of plasma from donors; MCS, which automate the collection of platelets; ACP that automate the process used to freeze, thaw, and wash red blood cells. The company's surgical blood salvage systems are used during and after surgery to collect a patient's own blood for reinfusion. These systems include Cell Saver brand systems for higher blood loss surgeries and trauma; OrthoPAT brand systems for lower, slower blood loss procedures; and cardioPAT brand system for blood loss during and after beating heart surgeries or for blood loss after various coronary artery bypass graft surgeries. The company offers its products primarily through direct sales force, independent distributors, and agents principally in the United Sates, Europe, and Japan and other parts of Asia. Haemonetics was founded in 1971 and is based in Braintree, Massachusetts.


ABIOMED, Inc. engages in the development, manufacture, and marketing of medical products to assist or replace the pumping function of the failing heart. ABIOMED manufactures and sells the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of patients with failing but potentially recoverable hearts. BVS and AB5000 are sold in the United States through direct sales and clinical support teams. In Europe, ABIOMED offers the Impella Recover minimally invasive cardiovascular support systems. Its AbioCor, which is in clinical trials, is a heart replacement device for the failing ventricles of a patient's diseased heart and takes over the heart's blood pumping function. ABIOMED conducts its international sales efforts through distributors and by selling directly in selected European markets through ABIOMED B.V., its wholly owned subsidiary. The company was founded by David M. Lederman in 1981. ABIOMED is headquartered in Danvers, Massachusetts.


Vascular Solutions, Inc., a medical device company, develops solutions to interventional cardiologists and radiologists. Its products include D-Stat Dry hemostatic bandage, a topical pad with a bandage used to control surface bleeding; Pronto extraction catheter, a mechanical system for the removal of soft thrombus from arteries; Vari-Lase endovenous laser, a laser and procedure kit used for the treatment of varicose veins; and Duett sealing device, which is used to seal the puncture site following catheterization procedures. The company also offers D-Stat Flowable hemostat, a mixture used to control bleeding; Langston dual lumen pigtail catheter that is used to measure intravascular pressure gradients; MAX-Support abdominal retraction belt, which is used to allow femoral access in obese patients, and Acolysis ultrasound, a treatment for peripheral occlusive arterial disease. Vascular Solutions offers its products to the physician in the United States and internationally through its direct domestic sales force and international distribution network. The company was founded by Howard Root. Vascular Solutions was incorporated in 1996 and is based in Minneapolis, Minnesota.


Pro-Dex, Inc engages in the design, development, and manufacture of electric, air, and battery powered rotary drive systems for the medical device and dental industries in the United States. Its rotary drive systems are used in the dental, cranial, spinal, arthroscopic, and orthopedic surgery. The company also designs and manufactures pneumatic motors and motion control systems for industrial applications in the automotive, aerospace, apparel, and entertainment industries. In addition, Pro-Dex develops motion control software and hardware for industrial and scientific applications. It also distributes its line of pneumatic and electric dental hand pieces under the brand Micro Motors' in North America. The company's products are used in hospitals, dental offices, medical engineering labs, scientific research facilities, and manufacturing operations. It distributes its products through its sales force and independent sales representatives within North America, as well as distributes through sales agreements with foreign distributors or through the domestic subsidiaries of foreign customers internationally. Pro-Dex was founded in 1978 and is headquartered in Santa Ana, California.


ev3, Inc., a medical device company, focuses on endovascular technologies for the minimally invasive treatment of vascular diseases and disorders. It operates in two segments, Cardio Peripheral and Neurovascular. The Cardio Peripheral segment includes cardiovascular products, which are used to treat coronary artery disease, atrial fibrillation, and other disorders in heart; and peripheral vascular products, which are used to treat vascular disease in legs, kidney, neck, and various other vascular diseases other than in the brain or the heart. Its peripheral vascular product line consists of peripheral stents, embolic protection devices, a carotid stenting system, thrombectomy devices, balloon angioplasty catheters, foreign object retrieval devices, and guidewires. This segment's cardiovascular product line includes embolic protection devices, thrombectomy devices, and stroke reduction devices, as well as Percutaneous Left Atrial Appendage Transcatheter Occlusion device designed to reduce the risk of stroke in patients with atrial fibrillation. The Neurovascular segment includes products that are used to treat vascular disease and disorders in the brain, including aneurysms and arterial-venous malformations. Its product portfolio comprises embolic coils; liquid embolics; and a range of neurovascular access and delivery products, such as microcatheters, occlusion balloon systems, and guidewires. The company's customers include cardiologists, radiologists, neuro-radiologists, vascular surgeons, neurosurgeons, and other endovascular specialists. ev3 markets its products in the United States, Europe, Canada, and Japan through a direct sales force, and through distributors in other international markets. The company is headquartered in Plymouth, Minnesota.


CryoCor, Inc., a medical technology company, engages in the development and manufacture of minimally invasive and disposable catheter systems for the treatment of cardiac arrhythmias in the United States. Its CryoCor Cardiac Cryoablation System treats cardiac arrhythmias through the use of cold or cryoenergy to ablate and destroy targeted cardiac cells for patients with atrial flutter and atrial fibrillation. CryoCor has strategic collaboration with Boston Scientific Corporation in the field of cryoablation for the treatment of cardiac arrhythmias. The company was incorporated in 2000 and is headquartered in San Diego, California.


AngioDynamics, Inc. engages in the design, development, manufacture, and marketing of medical devices for the minimally invasive diagnosis and treatment of peripheral vascular disease. Its products include angiographic catheters, hemodialysis catheters, plasma thromboplastin antecedent dilation catheters, thrombolytic products, image-guided vascular access products, endovascular laser venous system products, and drainage products. The company's therapeutic and diagnostic devices enable interventional radiologists, vascular surgeons, and others to treat peripheral vascular diseases and other noncoronary diseases. AngioDynamics sells its products primarily in the United States, Europe, and Japan. The company was co-founded by Eamonn P. Hobbs in 1988. It was formerly known as A.D., Inc. and changed its name to AngioDynamics, Inc. in 1996. AngioDynamics is headquartered in Queensbury, New York.


Merit Medical Systems, Inc. (MMS) engages in the development, manufacture, and marketing of disposable medical products primarily for use in the diagnosis and treatment of cardiovascular disease in the United States. The company's products consist of coronary control syringes; inflation devices and monitors; specialty syringes; high-pressure tubing and connectors; waste management products; disposable blood pressure transducer and pressure monitoring tubing; disposable hemostasis valves and accessories, and guide wire torque devices; manifolds and stopcocks; radial artery compression systems; contrast management systems; angiography needles and accessories; drainage catheters and accessories; pericardiocentesis catheters and procedure trays; thrombolytic infusion catheters and accessories; diagnostic angiographic pigtail catheters, diagnostic cardiology and radiology catheters, and marker band catheters; guide catheters; sheath introducers, vessel dilators, fixed and movable core, diagnostic guide wires and accessories, and hydrophilic guide wires; pressure infusor bags; and procedure trays. It serves hospital-based cardiologists, radiologists, anesthesiologists, physiatrists, neurologists, technicians, and nurses. MMS was founded by Fred P. Lampropoulos and Kent W. Stanger in 1987. The company is headquartered in South Jordan, Utah.


Bovie Medical Corporation engages in the manufacture and marketing of medical products and related technologies. It offers electrosurgical products, including generators, electrodes, electrosurgical pencils, and various ancillary disposable products used in surgery for the cutting and coagulation of tissue; battery operated cauteries, including replaceable battery and tip cauteries designed for precise hemostasis in ophthalmology; and nerve locator stimulator used for identifying motor nerves in hand and facial reconstructive surgery. Its other products include lighting instruments used in ophthalmology, general surgery, hip replacement surgery, and for the placement of endotracheal tubes in emergency and surgical procedures; and penlights used by physicians. The company operates in the United States, Europe, Asia, and Latin America. Bovie Medical Corporation was incorporated as An-Con Genetics, Inc. in 1982 and is based in Melville, New York.


Electro-Optical Sciences, Inc., a medical device company, designs and develops a non invasive, hand-held imaging, and point-of-care instrument to assist in the early detection of melanoma in the United States. Its principal product, MelaFind, features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. The data is then analyzed through its proprietary database of melanomas and benign lesions to provide information to the physician and produce a recommendation of whether the lesion should be biopsied. The company offers its product primarily for general dermatologists, plastic surgeons, and primary care physicians. Electro-Optical Sciences was founded in 1989 and is based in Irvington, New York.


Utah Medical Products, Inc. (UMP) engages in the development, manufacture, assembling, and marketing of disposable and reusable specialty medical devices. It offers medical devices used in critical care areas, especially the neonatal intensive care unit, and the labor and delivery department in hospitals, as well as products sold to outpatient clinics and physician's offices. The company's obstetrics products include fetal monitoring accessories, vacuum-assisted delivery systems, and other obstetrical tools. Its neonatal intensive care products include the DISPOSA-HOOD, an infant respiratory hood; DELTRAN PLUS, a blood pressure monitoring system; and umbilical vessel catheters. The company's other specialty products include a disposable peritoneal dialysis set, a silicone oral protection device used to prevent palatal soft tissue injury by orotracheal tubes, and a lumbar sampling kit for obtaining cerebral spinal fluid samples. UMP's gynecology/urology/and electro surgery products consists of the LETZ System that is used to excise cervical intraepithelial neoplasia and other lower genital tract lesions related to human papilloma virus infections; FINESSE electrosurgical system and specialized electrodes; EPITOME, an electrosurgical scalpel; LIBERTY System to treat urinary incontinence in women; PATHFINDER PLUS, an endoscopic irrigation device; ENDOCURETTE for uterine endometrial tissue sampling; and LUMIN for manipulation of the uterus in gynecological laparoscopic procedures. Its blood pressure monitoring line comprises DELTRAN disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. The company sells its products through direct sales representatives and independent manufacturers' representatives in the United States, as well as through specialty distributors, other medical device companies, and independent medical products distributors internationally. UMP was formed in 1978 and is headquartered in Midvale, Utah.


Boston Scientific Corporation engages in the development, manufacture, and marketing of medical devices that are used in interventional medical specialties. The company's products are offered by two groups, Cardiovascular and Endosurgery. The Cardiovascular organization provides products and technologies for use in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, and neurovascular procedures. The Endosurgery organization provides products and technologies for use in oncology, endoscopy, urology, and gynecology procedures. In addition, the company operates in the neuromodulation market. It provides products for the treatment of auditory disorders and chronic pain. The company's less-invasive medical products are used for enlarging narrowed blood vessels to prevent heart attack and stroke; clearing passages blocked by plaque to restore blood flow; opening obstructions and bringing relief to patients suffering from various forms of cancer; performing biopsies and intravascular ultrasounds; mapping electrical problems in the heart; placing filters to prevent blood clots from reaching the lungs, heart, or brain; treating urological, renal, pulmonary, neurovascular, and gastrointestinal diseases; and modulating nerve activity to treat deafness and chronic pain. The company markets its products through direct sales force, and a network of distributors and dealers. Boston Scientific Corp. has a collaboration agreement with Affinergy, Inc. to investigate new coatings for cardiovascular stents. The company was founded by John E. Abele and Peter M. Nicholas in 1979. Boston Scientific Corp. is headquartered in Natick, Massachusetts.


APA Enterprises, Inc. engages in the development, design, manufacture, and marketing of fiber optics, copper, and gallium nitride-based components and devices for industrial, commercial, consumer, and scientific applications. It operates in two segments, Optronics, and Cables and Networks. The Optronics segment offers ultraviolet measurement instruments for consumers and industrial customers, and gallium nitride-based transistors for power amplifiers and other commercial applications. The Cables and Networks segment designs and manufactures fiber optic connectivity solutions centered upon its fiber distribution system (FDS). The FDS product line supports various panel configurations, densities, connectors, and adapter options. This segment offers fiber distribution central office frame systems, fiber distribution outside plant cabinets, optical components, and cable assemblies. APA Enterprises distributes its products through direct sales force and manufacturer representative organizations. The company was founded in 1979 by Anil K. Jain. It was formerly known as APA Optics, Inc. and changed its name to APA Enterprises, Inc. in 2004. APA Enterprises is headquartered in Blaine, Minnesota.


Antares Pharma, Inc. operates as a specialty drug delivery/pharmaceutical company providing drug delivery systems for pharmaceuticals. The company's technology platforms include transdermal gels, fast-melt oral tablets, disposable minineedle injection systems, and reusable needle-free injection systems. Its transdermal drug delivery platform develops gels, which deliver medication with less potential for skin irritation, and avoiding the initial gastrointestinal and liver uptake problems of some orally ingested drugs. The company's fast-melt oral disintegrating tablets are designed to help patients experiencing difficulty in swallowing pills, tablets, or capsules. Its injection device platform features reusable needle-free injectors, which deliver precise medication doses through pressurized liquid penetration of the skin without a needle; disposable minineedle injectors, which are designed to provide subcutaneous injection capabilities with reduced discomfort and safety of a shielded needle; and emerging vaccine intradermal injectors. The company was incorporated in 1979 and was formerly known as Medi-Ject Corporation. Antares Pharma is headquartered in Exton, Pennsylvania.


Biolase Technology, Inc., a medical technology company, engages in the design, manufacture, and marketing of advanced dental, cosmetic, and surgical lasers and related products primarily in the United States and internationally. Its products include dental laser systems that allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform various dental procedures, including cosmetic and surgical applications. The company's laser system products include Waterlase system and Diode system. The Waterlase system uses a patented combination of water and laser to perform dental procedures performed using dental drills, scalpels, and other dental instruments for cutting soft and hard tissue. The Diode laser system uses a semiconductor diode laser to perform soft tissue and cosmetic procedures, including tooth whitening. In addition, the company manufactures and sells accessories and disposables for its laser systems, such as hand pieces, laser tips, and tooth whitening gelkits. Biolase Technology sells its products through its direct sales force and a network of independent distributors. The company was founded in 1984 and is headquartered in San Clemente, California.


Bioject Medical Technologies, Inc. engages in the development, manufacture, and distribution of needle-free drug delivery systems. The company's products include Biojector 2000, Drug Reconstitution System, and Vitajet. The Biojector 2000 is an injection system that enables healthcare professionals to deliver measured variable doses of medication through the skin, either intramuscularly or subcutaneously, without a needle. The Drug Reconstitution System allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. The Vitajet is designed for subcutaneous self-injection of insulin in the home. The company is also developing Iject prefilled device for delivery of its drug to treat a specific condition. It has licensing and/or development agreements with Ares Serono, PATH, and Merial for the development of needle-free injection systems. Bioject Medical was founded in 1985 and is headquartered in Bedminster, New Jersey.


Hillenbrand Industries, Inc. provides products and services for the health care and funeral services industries worldwide. It offers products for patient care environment, such as electrically adjustable hospital beds, stretchers, surgical table accessories, bedside cabinets, overbed tables, mattresses, and patient room furniture, as well as architectural products, such as headwalls and power columns. It also offers associated systems for wound, pulmonary, and circulatory care. In addition, the company provides biomedical equipment rentals and other services. The company also offers metal and hardwood caskets, cremation urns, and cremation-related products, as well as cremation marketing system for funeral service professionals. The company distributes its products directly, as well as through distributors. Hillenbrand was incorporated in 1969 and is headquartered in Batesville, Indiana.


Orthovita, Inc. engages in the development and marketing of synthetic-based biomaterial products for use in spine surgery, the repair of osteoporotic fractures, and a range of clinical needs in the trauma, joint reconstruction, revision, and extremities markets primarily in the United States. Its products include VITOSS bone graft substitute (VITOSS), IMBIBE bone marrow aspirate syringe (IMBIBE), ENDOSKELETON TA device, CORTOSS synthetic cortical bone void filler (CORTOSS), VITAGEL surgical hemostat, and ALIQUOT microdelivery system. VITOSS is an ultra-porous resorbable beta-tricalcium phosphate bone void filler used to enable the body guide the three-dimensional regeneration of the patient's own bone. The IMBIBE provides spine and orthopedic surgeons with a method for harvesting a patient's bone marrow, mixing it with VITOSS and delivering the mixture to the bone graft site. ENDOSKELETON TA device provides physiological support to, or replaces damaged vertebral bodies. The CORTOSS is a bone-bonding and self-setting composite engineered specifically to mimic the characteristics of human cortical bone. VITAGEL is a composite liquid hemostat that combines the biomaterials thrombin and collagen with the patient's autologous plasma for soft-tissue healing. The ALIQUOT microdelivery system facilitates delivery of the company's CORTOSS product directly to the surgical site. Orthovita also offers VITOMATRIX particulate synthetic scaffold biomaterial and bone graft substitute materials, such as VITOSS FOAM products, which combine VITOSS technology with resorbable biomaterials to produce an array of pliant, flexible, flowable, and compression resistant bone graft materials. In addition, the company distributes products, which compliment its biomaterial platforms. It sells its products through direct sales force, independent sales agency, and stocking distributors. Orthovita was incorporated in 1992 and is headquartered in Malvern, Pennsylvania.


Memry Corporation engages in the design, development, manufacture, and marketing of products and components primarily for the medical device industry. Its shape memory alloys product line comprises betatitanium alloy, semifinished materials, wire, strip, tube, formed components, and subassemblies. The company's specialty polymer extrusion product line includes co-extruded tubing, total intermittent extrusions tubing, thermoset polyimide tubing, single lumen, multilumen, taper/bump, braided reinforced tubing, and wire coating. It also offers medical device products, including stent components, catheter components, guidewires, laparoscopic surgical subassemblies, and orthopedic instruments, as well as complex, multilumen, and multilayer polymer extrusions used for guidewires, catheters, delivery systems, and various other interventional medical devices. In addition, the company provides engineering services to assist customers in the development of products based on the properties of shape memory alloys. It also provides sealing devices, actuators, and fasteners to the telecommunications, aerospace/defense, and automotive industries. Memry Corporation sells its products through direct sales force and sales representatives in the United States and Europe. The company was incorporated in 1981 and is headquartered in Bethel, Connecticut.


West Pharmaceutical Services, Inc. engages in the development, manufacture, and sale of components and systems used for injectable drug delivery worldwide. Its components include elastomeric stoppers and aluminum seals for vials, multipiece tamper-resistant plastic, and aluminum closures; and components used in syringe, intravenous, and blood collection systems. It also provides plastic systems and components for use in over the counter drugs, personal care, and food and beverage applications. The company provides components and/or contract services to pharmaceutical, biotechnology, and hospital supply/medical device companies. It distributes its products and services primarily through its own sales force and regional distributors. The company supports its partners and customers from 50 locations in North America, South America, Europe, Mexico, Japan, Asia, and Australia. West Pharmaceutical was founded in 1923 and is headquartered in Lionville, Pennsylvania.


Kensey Nash Corporation, a medical technology company, engages in the development and manufacture of absorbable biomaterials-based products with applications in the cardiology, orthopaedics, spine, drug and biologics delivery, periodontal/dental, surgical, and wound care markets. It primarily offers Angio-Seal vascular closure device, a device designed to seal and close femoral artery punctures made during diagnostic and therapeutic cardiovascular catheterizations; and TriActiv embolic protection system, a device designed to prevent microparticulate from traveling downstream during the treatment of diseased coronary saphenous vein bypass grafts. This system utilizes active flushing and extraction to remove debris from the vessel after a treatment procedure. The company also develops various bone graft substitutes fabricated from collagen, synthetic polymers, or composite biomaterials. Kensey Nash has a strategic alliance with St. Jude Medical, Inc. The company was founded in 1984 and is based in Exton, Pennsylvania.


The Cooper Companies, Inc. engages in the development, manufacture, and marketing of healthcare products worldwide. It operates in two segments, CooperVision and CooperSurgical. The CooperVision segment develops, manufactures, and markets a range of contact lenses for the vision care market. It specializes in toric lenses that correct astigmatism; cosmetic lenses, which change the appearance of the color of the eye; and other lenses. The CooperSurgical segment engages in the development, manufacture, and marketing of medical devices, diagnostic products, and surgical instruments and accessories, which are used primarily by gynecologists and obstetricians. The company markets its products through field sales representatives and distributors in the United States, Canada, the United Kingdom, Brazil, Portugal, Italy, Spain, France, Holland, Sweden, Norway, Australia, and South Africa. The company was organized in 1980 and is based in Pleasanton, California. The Cooper Companies, Inc. acquired Ocular Sciences, Inc., a contact lens manufacturer, in January 2005.


Mesa Laboratories, Inc. engages in the design, manufacture, and marketing of electronic instruments and supplies. Its product line consists of recording systems, which are used to measure temperature, humidity, and pressure inside a process or inside a product during manufacturing; fluid measurement components, such as flow meters, used in water treatment, chemical processing, and heating, ventilation, and air conditioning applications; and concentration analyzers and pipeline interface detectors, which are used in chemical, food, pharmaceutical, and polymerization processes. The company also manufactures and distributes electronic measurement systems for renal treatment, including dialysate meters and dialyzer reprocessing products used in kidney dialysis. Mesa Laboratories was incorporated in 1982 and is based in Lakewood, Colorado.


Encision, Inc., a medical device company, engages in the design, development, manufacture, and marketing of surgical instruments that provide safety to patients undergoing minimally-invasive surgery. It produces and markets a line of AEM Surgical Instruments, which prevents stray electrosurgical burns from insulation failure and capacitive coupling. The company's product line includes a range of articulating instruments that include scissors, graspers, and dissectors; fixed-tip electrodes; and suction-irrigation electrodes. In addition, Encision markets the AEM Monitor product line that is used in conjunction with the AEM Instruments. It sells products primarily to hospitals through a distribution network comprising direct and independent sales representatives in the United States. The company was founded in 1991 and is based in Boulder, Colorado.


ICU Medical, Inc. engages in the development, manufacture, and marketing of disposable medical connection systems for use in intravenous (I.V.) therapy applications. Its products include CLAVE, a one-piece, needleless I.V. connection device; custom I.V. systems; Punctur-Guard line of blood collection needles; CLC2000, one piece, swabable connector used to connect I.V. lines to catheters; 1o2 Valve, a one-way or two-way drug delivery system; and Lopez Enteral Valve, a small T' valve designed to be connected into nasogastric, gastric, or jejunostomy tube systems. The company's devices are designed to protect healthcare workers and their patients from exposure to infectious diseases, such as Hepatitis B and C and Human Immunodeficiency Virus, through accidental needlesticks. In addition, the company develops a family of single-use needleless connectors for use in piggyback and nonpiggyback applications. ICU Medical sells its products to I.V. product manufacturers and independent distributors. It distributes its products in the United States, Canada, western Europe, the Pacific Rim, Latin America, and South Africa. ICU Medical was founded by George A. Lopez and is based in San Clemente, California.


Young Innovations, Inc. engages in the development, manufacture, and marketing of supplies and equipment used to enable the practice of dentistry and to promote oral health. Its products include disposable and metal prophylaxis angles, prophylaxis cups and brushes, X-ray machines, moisture control products, infection control products, dental handpieces (drills) and related components, endodontic systems, orthodontic toothbrushes, flavored examination gloves, children's toothbrushes, and children's toothpastes, as well as ultrasonic systems and obturation products used in endodontic surgeries, such as root canal procedures. The company markets its products to dentists, endodontists, orthodontists, dental hygienists, and dental assistants primarily through a network of nonexclusive relationships with dental product distributors. In addition, Young Innovations sells directly to dental and dental hygiene schools, Veterans Administration healthcare facilities, and the U.S. military bases. It offers its products in North America, Europe, South America, Central America, and the Pacific Rim. The company was incorporated in 1995. It was formerly known as Young Dental and changed its name to Young Innovations, Inc. in 1995. Young Innovations is headquartered in Earth City, Missouri.


Endologix, Inc. engages in the development, manufacture, sale, and marketing of minimally invasive therapies for the treatment of vascular disease. Its primary focus is the development of the PowerLink System, a catheter-based alternative treatment to surgery for abdominal aortic aneurysms. This system consists of a self-expanding stainless steel stent cage covered with ePTFE, a common surgical graft material. The PowerLink endoluminal graft is implanted in the abdominal aorta, which is accessed through the femoral artery. The implantation causes the blood flow to be shunted away from the weakened or aneurysmal' section of the aorta resulting in the reduction of pressure and potential for the aorta to rupture. The company sells its products to its customers located in North America, Europe, Asia, and Latin America. Endologix is based in Irvine, California.


Home Diagnostics, Inc. develops, manufactures, and markets blood glucose monitoring systems and disposable supplies for people with diabetics worldwide. It offers blood glucose systems based on biosensor and photometric technology platforms. The biosensor meter technology measures glucose by using an amperometry method employing a glucose oxidase reaction. The photometric meter technology measures blood glucose by using membrane technology that employs a glucose oxidase/peroxidase reaction. The company markets its blood glucose monitoring systems products under Sidekick, TrueTrack Smart System, and Prestige IQ brands, as well as under a co-branded format. In addition, Home Diagnostics provides monitoring accessories, such as disease management software, which allows people with diabetes to record the results of their blood glucose tests and use tools to help identify ways in which they can manage consistent blood glucose levels; Gentle Draw lancing device that enables people with diabetes to obtain a blood sample for a blood glucose test; single-use sterile lancets; and disposable urinary test strips, which are used to test ketone levels in urine. The company sells its products through food and drug retailers, mass merchandisers, distributors, mail service providers, and third-party payors. Home Diagnostics was founded in 1985 and is based in Fort Lauderdale, Florida.


Advanced Medical Optics, Inc. (AMO) engages in the development, manufacture, and marketing of surgical devices for the eyes worldwide. It has two product lines, ophthalmic surgical and eye care. The company's ophthalmic surgical product line provides medical devices for use in the cataract and refractive surgery markets. Cataract surgery market focuses on four products, including foldable intraocular lenses (IOLs), implantation systems, phacoemulsification systems, and viscoelastics. Refractive surgery market, in addition to IOLs and viscoelastics, markets microkeratomes for use in the LASIK procedure. AMO's eye care product line provides a range of contact lens care products for use with various contact lenses. These products include single-bottle, multipurpose cleaning and disinfecting solutions, hydrogen peroxide-based disinfecting solutions, daily cleaners, enzymatic cleaners, and contact lens rewetting drops. The company's customers include surgeons, hospitals, ambulatory surgical centers, optometrists, opticians, ophthalmologists, and retailers, such as mass merchandisers and drug store chains. It has direct operations in approximately 20 countries; and markets and sells its products in approximately 60 countries, including Europe. AMO has operations in North and South America, Europe, Africa, Middle East, Japan, and Asia Pacific. Advanced Medical Optics was incorporated in 2001 and is based in Santa Ana, California.


CardioTech International, Inc. engages in the development and manufacture of small bore vascular grafts or synthetic blood vessels for the treatment of cardiovascular disease. It offers oxygenators, cardiovascular tubing systems, arterial filters, cardiotomy reservoirs, venous reservoirs, oxygen saturation monitors, orthofuser, cardioplegia units, and critical care central venous access catheters and ports that are used during open heart surgery, as well as develops CardioPass synthetic coronary artery bypass graft to treat coronary artery disease. The company also manufactures medical disposables on an original equipment manufacturing basis for the cardiology, interventional radiology, and critical care markets; supplies specialized disposable medical devices to medical device companies; and provides contract services. In addition, CardioTech International develops, manufactures, and markets polyurethane-based biomaterials for use in acute and chronically implanted devices, such as stents, artificial hearts, and vascular ports. It distributes products primarily through medical distributors in the United States and internationally. The company was founded in 1993 and is headquartered in Wilmington, Massachusetts.


Biosphere Medical, Inc. operates as a medical device company. It engages in the development, manufacture, and marketing of minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology to treat uterine fibroids, hypervascularized tumors, and vascular malformations. The company's products include Embosphere Microspheres, EmboGold Microspheres, Hepasphere SAP Microspheres, EmboCath Hydrophilic Infusion Catheter, and Segway Hydrophilic Guidewire. Embosphere Microspheres and EmboGold Microspheres are used for the treatment of hypervascularized tumors and arteriovenous malformations. Hepasphere SAP Microspheres are used for treatment of liver cancer. EmboCath Hydrophilic Infusion Catheter and Segway Hydrophilic Guidewire are used in peripheral embolization procedures. BioSphere Medical sells its products primarily in the United States and the European Union, as well as in Canada, Middle East, Africa, South America, and Asia. The company was incorporated in 1993. It was formerly known as BioSepra, Inc. and changed its name to BioSphere Medical, Inc. in 1999. BioSphere Medical is headquartered in Rockland, Massachusetts.


STEN Corporation engages in the operation of fast food restaurants, and in the provision of contract manufacturing services for medical products in the United States. The company operates in two segments: The Burger Time Acquisition Corporation (BTAC), and Contract Manufacturing. The BTAC segment operates a chain of fast-food, drive-through restaurants under the Burger Time name. The Contract Manufacturing segment provides contract manufacturing services for surgical instrument sterilization container systems and filters. STEN Corporation was incorporated in 1978 and was formerly known as Oxboro Medical, Inc. It changed its name to Sterion Incorporated in 2002 and to STEN Corporation in 2005. The company is headquartered in Ham Lake, Minnesota.


Angeion Corporation, through its subsidiary, Medical Graphics Corporation, engages in the development, manufacture, and marketing of noninvasive cardio-respiratory diagnostic systems used in the management and improvement of cardio-respiratory health. The company offers its products to health care professionals for the prevention, detection, and treatment of heart and lung disease. Its MedGraphics products include pulmonary function and cardiopulmonary exercise testing systems that operate with its proprietary BreezeSuite Windows2000/XP software to address the needs of hospitals, clinics, and physician offices. Angeion's pulmonary function systems consist of spirometry, pulmonary function systems, and body plethysmograph systems. In addition, it provides cardiopulmonary exercise testing systems, which measure functional capacity, fitness, or conditioning levels, as well as enable physicians to diagnose heart and lung diseases. Further, the company offers cycle ergometers and treadmills for use in diagnostic, rehabilitation, training, and sports medicine applications. Angeion markets its products in the United States through direct sales force, as well as through independent distributors internationally. It also sells health and fitness products through health and fitness clubs, personal training studios, weight loss centers, and other retail outlets. The company was founded in 1992 and is headquartered in Saint Paul, Minnesota.


Nephros, Inc. develops hemodiafiltration (HDF) products and technologies for treating patients with End Stage Renal Disease (ESRD). Its products include the company's proprietary Mid-Dilution Diafiltration technology, a fluid management system that removes renal toxins across the molecular spectrum. The company has three products in various stages of development, including OLpur MD190, a dialyzer designed for HDF therapy; the OLpur H2H, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy; and the OLpur NS2000 system, a stand-alone hemodiafiltration machine and associated filter technology. Nephros sells OLpur MD190 dialyzer in some or all of Cyprus, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom. The company was founded in 1997 and is based in New York City.


Implant Sciences Corporation engages in the development, manufacture, and marketing of products for the medical device and explosives detection industry. Its core technology involves ion implantation and thin film coatings of radioactive and nonradioactive materials. The company manufactures and sells I-Plant Iodine-125 radioactive seed for the treatment of prostate cancer, and Ytterbium-192 for breast cancer therapy. It also provides surface engineering technology to manufacturers of orthopedic hip and knee total joint replacements. Implant Sciences has also developed a trace explosives detection instrument, which detects the vapor from trace amounts of explosive compounds, including plastic explosives, such as RDX, the compound commonly found in C4 explosives. The company also provides ion implantation, and analytical services and equipment to the semiconductor manufacturers, research laboratories, and research universities. In addition, it is developing a device for the treatment of ocular melanoma using brachytherapy, as well as other radiation therapy devices in various stages of development, including devices for biliary duct cancer and dural irradiation. The company has a strategic alliance with Rapiscan Systems, Inc. for the manufacture and sale of explosives detection equipment on a private label basis. Implant Sciences was incorporated in 1984 and is based in Wakefield, Massachusetts.


NeuroMetrix, Inc., a medical device company, engages in the design, development, and sale of proprietary products used to diagnose neuropathies. Neuropathies are diseases of the peripheral nerves and parts of the spine that frequently are caused by or are associated with diabetes, low back pain, and carpal tunnel syndrome, as well as other clinical disorders. The company offers NC-stat System, a neuropathy diagnostic system that provides physicians the ability to diagnose patients with neuropathies at the point-of-service. The system comprises disposable NC-stat biosensors; the NC-stat monitor and related components; and the NC-stat docking station, an optional device that enables the physician to transmit data to the company's onCall Information System. NeuroMetrix also has products under development, such as devices for the treatment of neuropathy, new NC-stat biosensors and associated software for the medically appropriate testing of additional nerves, and third generation NC-stat monitor and docking station. As of April 27, 2005, the NC-stat System was used in approximately 2,400 physician's offices, clinics, and other health care facilities. The company markets its products through regional sales managers and independent regional sales agencies to physicians in the United States. NEUROMetrix was founded by Shai N. Gozani in 1996 and is headquartered in Waltham, Massachusetts.


Retractable Technologies, Inc. engages in the design, development, manufacture, and marketing of safety needle devices for the healthcare industry. It offers VanishPoint automated retraction safety syringes and blood collection devices, which eliminate health care worker exposure to accidental needlestick injuries. The company's products also include a dental syringe, a butterfly IV, a self retracting IV catheter introducer, and an auto-disable syringe. Its products are sold to and used by healthcare providers, which include acute care hospitals, alternate care facilities, doctors' offices, clinics, emergency centers, surgical centers, convalescent hospitals, veterans administration facilities, military organizations, public health facilities, and prisons. Retractable Technologies distributes its products through general line, specialty, and international distributors throughout the United States and its territories. Retractable Technologies was founded by Thomas J. Shaw. The company was incorporated in 1994 and is headquartered in Little Elm, Texas.


Vasogen, Inc., a development stage company, engages in the research and development of immune modulation therapies for chronic inflammation underlying cardiovascular disorders primarily in Canada. Its primary product, Celacade, is in two pivotal phase III clinical trials for the treatment of chronic heart failure and peripheral arterial disease. The company's another product VP025 is in preclinical development for the treatment of neurodegenerative disorders, including Parkinson's and Alzheimer's disease. Vasogen was founded in 1980 and is headquartered in Mississauga, Canada.


NMT Medical, Inc. engages in designing, developing, and marketing proprietary implant technologies that allow cardiologists to treat cardiac sources of migraine headaches, stroke, and other brain attacks through minimally invasive, catheter-based procedures. The company designs and develops implants that seal the patent foramen ovale defect. It also offers cardiac septal repair implants delivered with nonsurgical catheter techniques. The company manufactures CardioSEAL, a cardiac septal repair implant; and STARFlex, which incorporates a self-centering system that enables the implant to self-adjust to variations in the anatomy of a septal defect without deforming the septum or interfering with heart valve function. NMT Medical markets CardioSEAL through its direct sales force to customers in the United States and Canada, and markets CardioSEAL and STARFlex directly and through distributors in Europe. In addition, the company sells third party products for use with the CardioSEAL and STARFlex implant devices, principally vascular sizing balloons and sheaths. NMT Medical was co-founded by Morris Simon in 1986 and is headquartered in Boston, Massachusetts.


Inovio Biomedical Corporation, a biomedical company, engages in the development and commercialization of medical therapies for cancer using its Electroporation Therapy (EPT) technology. It focuses on building an oncology franchise based on its proprietary EPT technology. The therapy aims at selective killing of cancer cells and local ablation of solid tumors, while preserving healthy tissue. The company's lead product, MedPulser Electroporation Therapy System, is in premarketing studies for head and neck cancer, and skin cancer in Europe, as well as in phase III pivotal study for recurrent head and neck cancer in the United States. The system delivers electrical pulses to tumors injected with the generic drug bleomycin. Inovio's EPT technology is used by its partners for local delivery and cellular uptake of useful biopharmaceuticals in the development of DNA vaccines and gene therapies. In addition, the company is developing devices for the delivery of DNA for vaccinations and gene therapy. It has partnerships primarily with Merck & Co., Inc.; Vical Incorporated; University of South Florida Research Foundation, Inc.; Tripep AB; and Chiron. The company was incorporated in 1979 as Genetronics Biomedical, Ltd. and changed its name to Genetronics Biomedical Corporation in 2001, and then to Inovio Biomedical Corporation in March 2005. The company is headquartered in San Diego, California.


NUCRYST Pharmaceuticals Corp. develops, manufactures, and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. It produces nanocrystalline silver as a coating for wound dressing products under the trademark SILCRYST' and as a powder for use as an active pharmaceutical ingredient, which is known as NPI 32101. The company licenses its technology to Smith & Nephew plc, which markets, distributes, and sells products using the company's SILCRYST coatings. These products include Acticoat 3/Acticoat Burn Dressings; Acticoat 7 Dressings; Acticoat Absorbent Dressings; and Acticoat and Moisture Control Dressings. NUCRYST Pharmaceuticals' products are used by hospitals, clinics, burn centers, doctors, offices, home healthcare agencies, and nursing homes for the treatment of various wound types, such as chronic wounds, serious burns, and traumatic and surgical wounds. It also focuses on developing pharmaceutical products containing its NPI 32101 silver to extend the company's nanocrystalline silver technology to the treatment of gastrointestinal conditions. In addition, the company develops a topical cream containing NPI 32101 as a barrier to infection; and involves in the research of potential pharmaceutical products containing NPI 32101 for use in the treatment of gastrointestinal disorders. NUCRYST Pharmaceuticals was founded in 1997 and is headquartered in Wakefield, Massachusetts. NUCRYST Pharmaceuticals Corp. is a subsidiary of The Westaim Corporation.